Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06711822

The Safety and Performence of ShockPulse-10 in Patients with Coronary Artery Calcification

This study is an exploratory, multicenter, single-group clinical trial aimed to evaluate the clinical outcomes of using ShockPulse-10 in the treatment of coronary artery calcification .

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Anzhen Hosipital

Beijing, Beijing Municipality, 010, China

Location status: Recruiting

Location contact

Yanlong REN, Dortor

CONTACT

010-84005400

About this study

The study will be conducted at 8 sites in China and up to 205 participants will be followed for 180 days post procedure.

Patients ≥18 years of age scheduled for stent procedure with evidence of significant calcified stenosis of left main, or left anterior descending, right coronary artery or left circumflex will be eligible to enroll in the study. The primary endpoint of the study will evaluate procedure success,procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Patient is ≥ 18 years of age;
  • Patients with significant coronary artery disease (including stable or unstable angina and asymptomatic myocardial ischemia) who are suitable for PCI treatment;
  • A single newly developed stenosis of the target vessel, which is the left anterior descending artery, right coronary artery, or circumflex artery (or its branches), with stenosis degree ≥70% or ≥50% (Visually inspect ) and accompanied by evidence of ischemia;
  • The target lesion is a primary, in situ coronary artery lesion;
  • The reference vessel diameter for the target lesion is 2.0-4.0mm, and the length of the target lesion is ≤40mm (Visually inspect);
  • Visual assessment indicates that the lesion site can accommodate the passage of a pre-dilator or trial instrument through the lesion;
  • The target lesion site has moderate to severe calcification (meeting one of the following conditions):

① Angiography: Moderate calcification :clearer and more easily visible high-density shadows during cardiac pulsation; Severe calcification :clear high-density shadows both during and at rest;

② IVUS calcium score ≥2 points for superficial intimal, deep medial, and mixed calcification;

  • TIMI grade 3 in target vessel before registration (pre-dilation is allowed);

Key exclusion Criteria:

  • Left ventricular ejection fraction < 40%;
  • NYHA class III or IV heart failure;
  • Patients with single coronary artery supply;
  • Patients with evidence of dissection at the site of the lesion on imaging;
  • The imaging suggests that the vascular pathway is tortuous, making it difficult for the pre-dilatation device to reach the target location or to be retrieved;
  • Patients with active systemic infections;
  • Patients with uncontrollable severe hypertension (systolic pressure > 180 mmHg or diastolic pressure > 110 mmHg);
  • Patients with coagulopathy, hypercoagulable state or significant bleeding tendency (hemoglobin <10g/dL or platelet count <80×10^9/L);

Treatment and study plan

Shockplus-10

Device

Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians

Primary outcomes

  1. Procedure success

    Time frame: immediately post-procedure or prior to discharge, whichever comes first

    Procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization

  2. Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure

    Time frame: 30(±7days)days post index procedure

    Freedom from major adverse cardiac events (MACE) within 30(±7days) days of the index procedure;MACE is defined as:Cardiac death; or Myocardial Infarction (MI): or Target Vessel Revascularization

Study contacts

Contact information is provided by the study sponsor or research team.

XIANTAO SONG, Dortor

CONTACT

[email protected]

010-64412431

Sponsors and collaborators

Lead sponsor

Keya Medical

Industry

Registry information

Official study title

Prospective, Multicenter, Single-group Clinical Trial Evaluating the Safety and Effectiveness of ShockPulse-10 in the Treatment of Coronary Artery Calcification

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 2, 2024
Registry last updated
Dec 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.